Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers

PLoS One. 2013 Sep 20;8(9):e75184. doi: 10.1371/journal.pone.0075184. eCollection 2013.

Abstract

Background: MicroRNAs circulating in the blood, stabilized by complexation with proteins and/or additionally by encapsulation in lipid vesicles, are currently being evaluated as biomarkers. The consequences of their differential association with lipids/vesicles for their stability and use as biomarkers are largely unexplored and are subject of the present study.

Methods: The levels of a set of selected microRNAs were determined by quantitative reverse-transcription PCR after extraction from sera or vesicle- and non-vesicle fractions prepared from sera. The stability of these microRNAs after incubation with RNase A or RNase inhibitor, an inhibitor of RNase A family enzymes was studied.

Results: The levels of microRNA-1 and microRNA-122, but not those of microRNA-16, microRNA-21 and microRNA-142-3p, declined significantly during a 5-h incubation of the sera. RNase inhibitor prevented the loss of microRNAs in serum as well as the degradation of microRNA-122, a microRNA not expressed in blood cells, in whole blood. Stabilization of microRNA-122 was also achieved by hemolysis. Prolonged incubation of the sera led to enrichment of vesicle-associated relative to non-vesicle-associated microRNAs. Vesicle-associated microRNAs were more resistant to RNase A treatment than the respective microRNAs not associated with vesicles.

Conclusions: Serum microRNAs showed differential stability upon prolonged incubation. RNase inhibitor might be useful to robustly preserve the pattern of cell-free circulating microRNAs. In the case of microRNAs not expressed in blood cells this can also be achieved by hemolysis. Vesicle-associated microRNAs appeared to be more stable than those not associated with vesicles, which might be useful to disclose additional biomarker properties of miRNAs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / blood*
  • Enzyme Inhibitors / pharmacology
  • Erythrocytes / metabolism*
  • Healthy Volunteers
  • Humans
  • MicroRNAs / blood*
  • MicroRNAs / chemistry*
  • RNA Stability
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribonuclease, Pancreatic / antagonists & inhibitors
  • Serum / metabolism*

Substances

  • Biomarkers, Tumor
  • Enzyme Inhibitors
  • MicroRNAs
  • Ribonuclease, Pancreatic

Grants and funding

This work was supported in part by grants from the Paul und Ursula Klein-Stiftung (to VK) and the Deutsche Forschungsgemeinschaft (GRK1172) and the Scholari Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.